Skip to main content
. 2020 Oct 20;12(10):3048. doi: 10.3390/cancers12103048

Figure 2.

Figure 2

Kaplan–Meier survival curve of overall survival (OS). The median follow-up duration was 5.53 (IQR 2.88–10.38) months and 11 patients died of HCC progression. The median periods of OS since the initiation of lenvatinib therapy and since ICI therapy initiation were 15.8 months (95% CI: 8.5–23.2) and 29.8 months (95% CI: 25.3–34.4), respectively, for 36 patients.